Article Information
History
- April 30, 2021.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license.
Author Information
- L Lucaciu1,2,
- N Constantine-Cooke3,
- N Plevris1,
- S Siakavellas1,
- LAAP Derikx1,4,
- GR Jones1,5 and
- CW Lees1,6,*
- 1Edinburgh IBD Unit, Western General Hospital, Edinburgh, Scotland, UK
- 2Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania
- 3MRC Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Western General Hospital, Edinburgh, Scotland, UK
- 4Inflammatory Bowel Disease Centre, Department of Gastroenterology and Hepatology, Radboud University Medical Centre, Nijmegen, the Netherlands
- 5Centre for Inflammation Research, The Queen’s Medical Research Institute, University of Edinburgh, Scotland, UK
- 6Centre for Genomics and Experimental Medicine, Institute of Genetics and Molecular Medicine, University of Edinburgh, Western General Hospital, Edinburgh, Scotland, UK
- ↵*Address for correspondence
Professor Charles W. Lees PhD FRCP(Ed), Centre for Genomics and Experimental Medicine, Institute of Genetics and Molecular Medicine, University of Edinburgh, Western General Hospital, Edinburgh, EH4 2XU, UK 0131 6518500, Charlie.lees{at}ed.ac.uk
Author contributions LL, NP, SS – conception and study design, data collection, analysis and interpretation, writing of manuscript. LL and NP - quality assessment of the studies. NC-C - data collection and statistical analysis, writing of the manuscript. GRJ, LAAPD - writing of the manuscript and critical revision of the manuscript. CWL – conception and study design, writing of the manuscript and critical revision of manuscript. LL had full access to all the data in this study and takes responsibility for the accuracy and integrity of the data analysis. All authors approved the final draft of the manuscript.
Posted April 30, 2021.
Real-world experience with tofacitinib in ulcerative colitis - a systematic review and meta-analysis
